Reported 2 days ago
H.C. Wainwright has upheld a Buy rating for Agios Pharmaceuticals (NASDAQ:AGIO) while reducing the price target from $61 to $56. This decision follows a commercial and distribution agreement with Avanzanite for Agios' drug Pyrukynd in Europe, aimed at allowing Agios to focus on the US market. Despite concerns over the potential revenue split favoring Avanzanite, analyst Emily Bodnar believes this collaboration will help Agios accelerate its growth in European markets.
Source: YAHOO